Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 48
Filter
1.
J Neurovirol ; 27(3): 510-513, 2021 06.
Article in English | MEDLINE | ID: mdl-33876412

ABSTRACT

Progressive multifocal leucoencephalopathy is a serious side effect of natalizumab, a humanized monoclonal antibody approved for the treatment of multiple sclerosis. Here, we report a case of unexpected worsening of natalizumab-related progressive multifocal leucoencephalopathy following COVID-19. After natalizumab discontinuation, a slight neurological improvement was observed, but, two months later the patient was admitted to the hospital because of neurological deterioration and COVID-19 mild pneumonia. Except for SARS-CoV-2 infection, no other potential factors of neurological worsening were identified. Thus, we pose the hypothesis that SARS-CoV-2 was instrumental in the progressive multifocal leucoencephalopathy deterioration.


Subject(s)
COVID-19/complications , Leukoencephalopathy, Progressive Multifocal/chemically induced , Multiple Sclerosis, Relapsing-Remitting/drug therapy , Natalizumab/adverse effects , Humans , Immunologic Factors/adverse effects , Male , Middle Aged , Multiple Sclerosis, Relapsing-Remitting/complications , Pneumonia/virology , SARS-CoV-2
2.
Rev Neurol (Paris) ; 177(8): 935-940, 2021 Oct.
Article in English | MEDLINE | ID: mdl-33637293

ABSTRACT

BACKGROUND: In countries where fingolimod is available as first-line therapy without restrictions, we have an opportunity to observe long-term efficacy profile of this drug in treatment-naive patients according to their initial disease activity. METHODS: We retrospectively analysed the data of RRMS patients treated with FTY, focusing on 2 groups: 17 highly active patients (HA) defined as follows: ≥2 relapses in the year before treatment initiation and either≥1 Gd-enhancing T1 lesion or a significant increase in T2 lesion load from a baseline MRI; and 37 "not highly active" (NHA). We reviewed treatment efficacy (defined as NEDA-3), reasons for discontinuation and treatment tolerance in both groups. RESULTS: Mean follow-up duration was 48.2 months, SD 18.4. Fingolimod efficiently reduced relapses (NHA 90.3% reduction, P<0.001, HA 84.9%, P<0.001), and new Gd enhancing lesions (NHA 85.4% reduction, P=0.019, HA 92.3%, P=0.043). The proportion of patients reaching NEDA-3 status was higher in the NHA group (NHA: 80% at 2 years and 66% at 4 years, HA: 58% at 2 years and 38% at 4 years, P=0.042). Fingolimod was discontinued in 20 cases, mainly because of lack of efficacy (n=15). CONCLUSIONS: FTY is efficient in reducing relapses and new Gd enhancing lesions in both HA and NHA patients although the probability of achieving NEDA-3 over time is higher in early-treated treatment-naive NHA patients.


Subject(s)
Fingolimod Hydrochloride , Multiple Sclerosis, Relapsing-Remitting , Fingolimod Hydrochloride/therapeutic use , Humans , Immunosuppressive Agents/therapeutic use , Magnetic Resonance Imaging , Retrospective Studies , Treatment Outcome
3.
Rev Neurol (Paris) ; 177(1-2): 93-99, 2021.
Article in English | MEDLINE | ID: mdl-32771209

ABSTRACT

BACKGROUND: The current treated MS population is very different from that of patients in randomized clinical trials. OBJECTIVES: To study the long-term efficacy and tolerance of fingolimod (FTY) and dimethyl fumarate (DMF), both available as first-line treatment in early-treated treatment-naïve MS patients. METHODS: Retrospective analysis of 75 patients from our prospective MS registry fulfilling the inclusion criteria: FTY or DMF as first-line treatment, treatment initiation within 36months of disease onset and treatment duration>12months. RESULTS: Demographics and MRI characteristics at baseline were similar in both groups (FTY 55 patients, DMF 20), but patients on FTY had higher pretreatment clinical activity (P=0.008). Twenty-two percent of patients in the FTY group and 15% in the DMF group had highly active disease. At last follow-up (mean: 44.2, SD: 17.3months), the majority of the patients were still on treatment while 54.5% of FTY and 65% of DMF patients reached NEDA 3 status (P=0.444). Both treatments significantly decreased relapses and occurrence of new T1 Gd-enhancing lesions (P<0.001). The main reason for discontinuation was disease activity without severe side effects on either treatment. CONCLUSIONS: Our findings support efficacy and tolerance of both drugs in early-treated treatment-naive MS patients, arguing in favour of efficient early immunomodulation in MS patients. Both drugs significantly reduced the incidence of new relapses and Gd-enhancing lesions on treatment with FTY being more frequently prescribed than DMF, especially in patients with evidence of higher clinical disease activity.


Subject(s)
Multiple Sclerosis , Dimethyl Fumarate , Humans , Immunosuppressive Agents , Prospective Studies , Retrospective Studies , Treatment Outcome
6.
HIV Med ; 21(5): 342-348, 2020 05.
Article in English | MEDLINE | ID: mdl-31883203

ABSTRACT

OBJECTIVES: Diagnosing neurocognitive impairment (NCI) in HIV infection requires time-consuming neuropsychological assessment. Screening tools are needed to identify when neuropsychological referral is indicated. We examined the positive and negative predictive values (PPVs and NPVs, respectively) of the three European AIDS Clinical Society (EACS) screening questions in identifying NCI. METHODS: The Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study recruited patients aged ≥45 years enrolled in the Swiss HIV Cohort Study between 1 May 2013 and 30 November 2016. NAMACO participants (1) answered EACS screening questions, (2) underwent standardized neuropsychological assessment and (3) completed self-report forms [Center for Epidemiologic Studies Depression Scale (CES-D)] rating mood. NCI categories were defined using Frascati criteria. PPVs and NPVs of the EACS screening questions in identifying NCI categories were calculated. RESULTS: Of 974 NAMACO participants with complete EACS screening question data, 244 (25.1%) expressed cognitive complaints in answer to at least one EACS screening question, of whom 51.3% had NCI (26.1% HIV-associated and 25.2% related to confounding factors). The PPV and NPV of the EACS screening questions in identifying HIV-associated NCI were 0.35 and 0.7, respectively. Restricting analysis to NCI with functional impairment or related to confounding factors, notably depression, the NPV was 0.90. Expressing cognitive complaints for all three EACS screening questions was significantly associated with depression (P < 0.001). CONCLUSIONS: The EACS screening questions had an NPV of 0.7 for excluding patients with HIV-associated NCI as defined by Frascati criteria. The PPV and NPV may improve if NCI diagnoses are based on new criteria.


Subject(s)
Cognitive Dysfunction/diagnosis , HIV Infections/psychology , Cognitive Aging , Cognitive Dysfunction/etiology , Europe , Female , Humans , Longitudinal Studies , Male , Mental Status and Dementia Tests , Middle Aged , Prospective Studies , Societies, Medical , Surveys and Questionnaires
7.
HIV Med ; 21(1): 30-42, 2020 01.
Article in English | MEDLINE | ID: mdl-31589807

ABSTRACT

OBJECTIVES: The aim of the study was to examine baseline neurocognitive impairment (NCI) prevalence and factors associated with NCI among patients enrolled in the Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study. METHODS: The NAMACO study is an ongoing, prospective, longitudinal, multicentre and multilingual (German, French and Italian) study within the Swiss HIV Cohort Study. Between 1 May 2013 and 30 November 2016, 981 patients ≥ 45 years old were enrolled in the study. All underwent standardized neuropsychological (NP) assessment by neuropsychologists. NCI was diagnosed using Frascati criteria and classified as HIV-associated or as related to other factors. Dichotomized analysis (NCI versus no NCI) and continuous analyses (based on NP test z-score means) were performed. RESULTS: Most patients (942; 96.2%) had viral loads < 50 HIV-1 RNA copies/mL. NCI was identified in 390 patients (39.8%): 263 patients (26.8%) had HIV-associated NCI [249 patients (25.4%) had asymptomatic neurocognitive impairment (ANI)] and 127 patients (13%) had NCI attributable to other factors, mainly psychiatric disorders. There was good correlation between dichotomized and continuous analyses, with NCI associated with older age, non-Caucasian ethnicity, shorter duration of education, unemployment and longer antiretroviral therapy duration. CONCLUSIONS: In this large sample of aging people living with HIV with well-controlled infection in Switzerland, baseline HIV-associated NCI prevalence, as diagnosed after formal NP assessment, was 26.8%, with most cases being ANI. The NAMACO study data will enable longitudinal analyses within this population to examine factors affecting NCI development and course.


Subject(s)
HIV Infections/epidemiology , HIV/physiology , Neurocognitive Disorders/epidemiology , RNA, Viral/genetics , Age Factors , Comorbidity , Female , HIV Infections/psychology , HIV Infections/virology , Humans , Longitudinal Studies , Male , Middle Aged , Neurocognitive Disorders/etiology , Neuropsychological Tests , Prevalence , Prospective Studies , Risk Factors , Switzerland/epidemiology , Viral Load
8.
Eur J Clin Microbiol Infect Dis ; 34(10): 2049-55, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26282789

ABSTRACT

CSF lactate measurement is recommended when nosocomial meningitis is suspected, but its value in community-acquired bacterial meningitis is controversial. We evaluated the diagnostic performance of lactate and other CSF parameters in a prospective cohort of adult patients with acute meningitis. Diagnostic accuracy of lactate and other CSF parameters in patients with microbiologically documented episodes was assessed by receiver operating characteristic (ROC) curves. The cut-offs with the best diagnostic performance were determined. Forty-five of 61 patients (74%) had a documented bacterial (n = 18; S. pneumoniae, 11; N. meningitidis, 5; other, 2) or viral (n = 27 enterovirus, 21; VZV, 3; other, 3) etiology. CSF parameters were significantly different in bacterial vs. viral meningitis, respectively (p < 0.001 for all comparisons): white cell count (median 1333 vs. 143/mm(3)), proteins (median 4115 vs. 829 mg/l), CSF/blood glucose ratio (median 0.1 vs. 0.52), lactate (median 13 vs. 2.3 mmol/l). ROC curve analysis showed that CSF lactate had the highest accuracy for discriminating bacterial from viral meningitis, with a cutoff set at 3.5 mmol/l providing 100% sensitivity, specificity, PPV, NPV, and efficiency. CSF lactate had the best accuracy for discriminating bacterial from viral meningitis and should be included in the initial diagnostic workup of this condition.


Subject(s)
Cross Infection/diagnosis , Lactic Acid/blood , Meningitis, Bacterial/blood , Meningitis, Bacterial/diagnosis , Meningitis, Viral/blood , Meningitis, Viral/diagnosis , Receptors, Colony-Stimulating Factor/blood , Adolescent , Adult , Aged , Aged, 80 and over , Cohort Studies , Female , Humans , Male , Middle Aged , Prospective Studies , Sensitivity and Specificity , Switzerland , Young Adult
9.
Rev Med Suisse ; 11(461): 411-7, 2015 Feb 11.
Article in French | MEDLINE | ID: mdl-25895220

ABSTRACT

Giant cell arteritis (GCA) is a subacute/chronic vasculitis and represents the most common form of systemic vasculitis in people over the age of 50 years. The absence of clear and specific diagnostic criteria with the highly variable clinical presentation is a diagnostic challenge requesting a multidisciplinary approach. Yet, GCA is an emergency and the treatment must be initiated very rapidly due to the risk of blindness. This article presents a review of GCA as well as the diagnostic and therapeutic institutional guidelines of the University Hospital of Lausanne.


Subject(s)
Giant Cell Arteritis/drug therapy , Giant Cell Arteritis/therapy , Algorithms , Hospitals, University , Humans , Practice Guidelines as Topic , Switzerland
10.
Rev Neurol (Paris) ; 170(10): 577-83, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25189678

ABSTRACT

Viral infections can be a major thread for the central nervous system (CNS), therefore, the immune system must be able to mount a highly proportionate immune response, not too weak, which would allow the virus to proliferate, but not too strong either, to avoid collateral damages. Here, we aim at reviewing the immunological mechanisms involved in the host defense in viral CNS infections. First, we review the specificities of the innate as well as the adaptive immune responses in the CNS, using several examples of various viral encephalitis. Then, we focus on three different modes of interactions between viruses and immune responses, namely human Herpes virus-1 encephalitis with the defect in innate immune response which favors this disease; JC virus-caused progressive multifocal leukoencephalopathy and the crucial role of adaptive immune response in this example; and finally, HIV infection with the accompanying low grade chronic inflammation in the CNS in some patients, which may be an explanation for the presence of cognitive disorders, even in some well-treated HIV-infected patients. We also emphasize that, although the immune response is generally associated with viral replication control and limited cellular death, an exaggerated inflammatory reaction can lead to tissue damage and can be detrimental for the host, a feature of the immune reconstitution inflammatory syndrome (IRIS). We will briefly address the indication of steroids in this situation.


Subject(s)
Encephalitis, Viral/immunology , Immune System/immunology , Central Nervous System/immunology , Humans , Immunity, Innate
11.
Rev Med Suisse ; 10(427): 908, 910-2, 2014 Apr 23.
Article in French | MEDLINE | ID: mdl-24843987

ABSTRACT

Various neurological and neuropsychological manifestations are still relatively frequently reported in HIV infected patients in the highly active antiretroviral therapy era. A fraction of them could be related to HIV replication in the central nervous system (CNS) despite adequate peripheral viral suppression. This hypothesis is supported by numerous reports of detectable HIV RNA in the cerebrospinal fluid in the context of a low or undetectable viremia in association with neurological or neuropsychological complaints. In addition, some antiviral molecules may not achieve adequate levels in the CNS, thus potentially favoring intracerebral HIV replication and even antiretroviral resistance. Neurologic manifestations in the presence of CNS HIV replication often decrease after antiretroviral treatment CNS penetration optimization.


Subject(s)
Brain Diseases/virology , HIV Infections/virology , Virus Replication , Anti-Retroviral Agents/therapeutic use , HIV Infections/drug therapy , Humans , RNA, Viral/cerebrospinal fluid
12.
13.
Rev Med Suisse ; 9(384): 909-14, 2013 May 01.
Article in French | MEDLINE | ID: mdl-23717899

ABSTRACT

Anti-neuronal antibodies are implicated in various neurological syndromes that are sometimes associated with tumors. Depending on the antigenic target (nuclear, cytoplasmic or extracellular cell-surface or synaptic) the clinical presentation is different. In neurological syndromes associated with antibodies specific for intracellular antigens, the T-cell mediated immunological response predominates as pathogenic effector and the response to treatment is typically poor. In contrast, in syndromes related to antibodies against extracellular targets, the role of the antibodies is pathogenic and the neurological syndrome often responds better to immunomodulatory treatment, associated or not with an anti-tumoral treatment. We review the spectrum of anti-neuronal antibodies and their corresponding clinical and therapeutic characteristics.


Subject(s)
Autoantibodies/immunology , Neurons/immunology , Antigens, Nuclear/immunology , Cytoplasm/immunology , Humans
14.
Rev Med Suisse ; 9(384): 934-9, 2013 May 01.
Article in French | MEDLINE | ID: mdl-23717903

ABSTRACT

This review describes some dysimmune neuromuscular disorders and their recent management: syndrome of peripheral nerve hyperexcitability (treatment of cramps, immunosuppressors); Guillain-Barré syndrome (new mechanisms and consensus treatment); chronic inflammatory demyelinating polyradiculoneuropathy (new indication for the use of pulse dexamethasone, new scores of activity); importance of subcutaneous immunoglobulin in multifocal motor neuropathy and of infusions of rituximab in myasthenia gravis; new entities in myositis and their treatment.


Subject(s)
Neuromuscular Diseases , Humans , Neuromuscular Diseases/diagnosis , Neuromuscular Diseases/immunology , Neuromuscular Diseases/therapy
15.
Rev Med Suisse ; 9(384): 940-3, 2013 May 01.
Article in French | MEDLINE | ID: mdl-23717904

ABSTRACT

A new therapeutic era opened for multiple sclerosis (MS) with the appearance of molecules given p.o. and/or molecules with greater efficiency. Early diagnosis is critical, as the time and the choice of therapeutic intervention. The initiation of treatments must be personalized, including the risks associated with MS and those potentially related to the treatment chosen, answering the question >. Monitoring tools that allow to objectively evaluate: I) MS activity and aggressiveness for each patient and 2) the safety of treatments and their risks of complications, must be further investigated.


Subject(s)
Multiple Sclerosis/drug therapy , Drug-Related Side Effects and Adverse Reactions , Humans
16.
Rev Med Suisse ; 9(368): 62-5, 2013 Jan 09.
Article in French | MEDLINE | ID: mdl-23367707

ABSTRACT

In 2012, intramuscular midazolam appears as effective as intravenous lorezepam for the first line treatment of convulsive status epilepticus. Perampanel, a new anti-epileptic drug, will be soon available. Two oral treatments are now available for stroke prevention in atrial fibrillation setting. The methylphenidate and the Tai Chi could increase the walk capacity of patients suffering from Parkinson disease. A comprehensive cardiac work-up is essential for some congenital myopathy. A new drug against migraine seems free from vasoconstrictive effect. Antioxidants are harmful in Alzheimer disease. Some oral medication will be available for multiple sclerosis.


Subject(s)
Neurology/trends , Anticonvulsants/therapeutic use , Cerebrovascular Disorders/therapy , Dementia/therapy , Dyskinesias/therapy , Epilepsy/drug therapy , Humans , Mental Disorders/therapy , Neuroimmunomodulation/physiology , Neurology/methods , Neuromuscular Diseases/therapy , Therapies, Investigational/methods , Therapies, Investigational/trends
18.
Neurology ; 78(7): 458-67; discussion 465, 2012 Feb 14.
Article in English | MEDLINE | ID: mdl-22302546

ABSTRACT

OBJECTIVES: Progressive multifocal leukoencephalopathy (PML) has become much more common with monoclonal antibody treatment for multiple sclerosis and other immune-mediated disorders. METHODS: We report 2 patients with severe psoriasis and fatal PML treated for ≥3 years with efalizumab, a neutralizing antibody to αLß2-leukointegrin (LFA-1). In one patient, we conducted serial studies of peripheral blood and CSF including analyses of leukocyte phenotypes, migration ex vivo, and CDR3 spectratypes with controls coming from HIV-infected patients with PML. Extensive pathologic and histologic analysis was done on autopsy CNS tissue of both patients. RESULTS: Both patients developed progressive cognitive and motor deficits, and JC virus was identified in CSF. Despite treatment including plasma exchange (PE) and signs of immune reconstitution, both died of PML 2 and 6 months after disease onset. Neuropathologic examination confirmed PML. Efalizumab treatment was associated with reduced transendothelial migration by peripheral T cells in vitro. As expression levels of LFA-1 on peripheral T cells gradually rose after PE, in vitro migration increased. Peripheral and CSF T-cell spectratyping showed CD8+ T-cell clonal expansion but blunted activation, which was restored after PE. CONCLUSIONS: From these data we propose that inhibition of peripheral and intrathecal T-cell activation and suppression of CNS effector-phase migration both characterize efalizumab-associated PML. LFA-1 may be a crucial factor in homeostatic JC virus control.


Subject(s)
Antibodies, Monoclonal/adverse effects , JC Virus/physiology , Leukoencephalopathy, Progressive Multifocal/chemically induced , Lymphocyte Function-Associated Antigen-1/physiology , Aged , Antibodies, Monoclonal/metabolism , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized , Brain/pathology , CD4-Positive T-Lymphocytes/physiology , CD8-Positive T-Lymphocytes/physiology , Cell Movement , Fatal Outcome , Humans , Immune Reconstitution Inflammatory Syndrome/chemically induced , Immune Reconstitution Inflammatory Syndrome/complications , Immune Reconstitution Inflammatory Syndrome/psychology , Immunohistochemistry , Leukoencephalopathy, Progressive Multifocal/virology , Magnetic Resonance Imaging , Male , Memory Disorders/chemically induced , Mental Disorders/chemically induced , Mental Disorders/psychology , Middle Aged , Nervous System Diseases/chemically induced , Nervous System Diseases/psychology , Paresis/chemically induced , Perceptual Disorders/chemically induced , Plasma Exchange , Psoriasis/complications , Psoriasis/drug therapy
19.
Case Rep Med ; 2012: 239719, 2012.
Article in English | MEDLINE | ID: mdl-22312369

ABSTRACT

Posttransplant lymphoproliferative disorder (PTLD) is a potentially fatal complication of solid organ transplantation. The majority of PTLD is of B-cell origin, and 90% are associated with the Epstein-Barr virus (EBV). Lymphomatoid granulomatosis (LG) is a rare, EBV-associated systemic angiodestructive lymphoproliferative disorder, which has rarely been described in patients with renal transplantation. We report the case of a patient with renal transplantation for SLE, who presented, 9 months after renal transplantation, an EBV-associated LG limited to the intracranial structures that recovered completely after adjustment of her immunosuppressive treatment. Nine years later, she developed a second PTLD disorder with central nervous system initial manifestation. Workup revealed an EBV-positive PTLD Burkitt lymphoma, widely disseminated in most organs. In summary, the reported patient presented two lymphoproliferative disorders (LG and Burkitt's lymphoma), both with initial neurological manifestation, at 9 years interval. With careful reduction of the immunosuppression after the first manifestation and with the use of chemotherapy combined with radiotherapy after the second manifestation, our patient showed complete disappearance of neurologic symptoms and she is clinically well with good kidney function. No recurrence has been observed by radiological imaging until now.

20.
Rev Med Suisse ; 8(323): 46-50, 2012 Jan 11.
Article in French | MEDLINE | ID: mdl-22303740

ABSTRACT

In 2011, new oral anticoagulants for atrial fibrillation are available and the ABCD3-I score predicting stroke after TIA updates the ABCD2 score. New McDonald criteria allow faster MS diagnosis and the first oral treatment (fingolimod) for MS can be prescribed. A new anti-antiepileptic drug (retigabine) is available and sodium valproate has long term neurological adverse effects after in utero exposure. Among Parkinson disease treatments, deep brain stimulation is extending applications and dopamine agonists with extended release are as efficient and well tolerated as standard forms at long term scale. Monoclonal antibodies and immunosuppressant agents are proposed as good alternatives in the treatment of chronic dysimmune polyneuropathies. Gene therapy for the treatment of genetic myopathies is progressing.


Subject(s)
Atrial Fibrillation , Epilepsy , Ischemic Attack, Transient , Multiple Sclerosis , Muscular Diseases , Parkinson Disease , Polyneuropathies , Antibodies, Monoclonal/therapeutic use , Anticonvulsants/therapeutic use , Atrial Fibrillation/diagnosis , Atrial Fibrillation/drug therapy , Carbamates/therapeutic use , Chronic Disease , Deep Brain Stimulation , Dopamine Agonists/therapeutic use , Epilepsy/diagnosis , Epilepsy/drug therapy , Fingolimod Hydrochloride , Genetic Therapy/methods , Humans , Immunosuppressive Agents/therapeutic use , Ischemic Attack, Transient/diagnosis , Ischemic Attack, Transient/drug therapy , Ischemic Attack, Transient/etiology , Ischemic Attack, Transient/prevention & control , Multiple Sclerosis/diagnosis , Multiple Sclerosis/drug therapy , Muscular Diseases/diagnosis , Muscular Diseases/genetics , Muscular Diseases/therapy , Neurology/trends , Parkinson Disease/diagnosis , Parkinson Disease/drug therapy , Phenylenediamines/therapeutic use , Polyneuropathies/diagnosis , Polyneuropathies/drug therapy , Propylene Glycols/therapeutic use , Sphingosine/analogs & derivatives , Sphingosine/therapeutic use , Stroke/drug therapy , Treatment Outcome , Valproic Acid/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...